Abstract
Background Brazil detected community transmission of COVID-19 on March 13, 2020. In this study we identify which areas in the country are most vulnerable for COVID-19, both in terms of the risk of arrival of COVID-19 cases and the risk of sustained transmission. The micro-regions with higher social vulnerability are also identified.
Methods Probabilistic models were used to calculate the probability of COVID-19 spread from São Paulo and Rio de Janeiro, according to previous data available on human mobility in Brazil. We also perform a multivariate cluster analysis of socio-economic indices to identify areas with similar social vulnerability.
Results The results consist of a series of maps of effective distance, outbreak probability, hospital capacity and social vulnerability. They show areas in the North and Northeast with high risk of COVID-19 outbreak that are also highly vulnerable.
Interpretation The maps produced are useful for authorities in their efforts to prioritize actions such as resource allocation to mitigate the effects of the pandemic and may help other countries to use a similar approach to predict the virus route in their countries as well.
Funding No funding
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
D.V. is a CNPq/Brazil Fellow, R.M.L is a INOVA/Fiocruz Fellow
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will become available after peer-review
